NCT05043402View on ClinicalTrials.gov

A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

August 15, 2024

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

navicixizumab

navicixizumab IV

DEVICE

Xerna™ TME Panel

RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).

Sponsors
All Listed Sponsors
lead

OncXerna Theraputics, Inc.

INDUSTRY